Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

Impact · against what's priced in

ROIV gains a commercial foundation following the regulatory approval of LISRAYA. Further upside depends on the execution of Phase 3 trials for mosliciguat and potential indication expansion for brepocitinib.

ROIV+0.60: No priced-in read yet
In context: The regulatory approval of LISRAYA transitions the company from a pure R&D play to one with a commercial foundation, while Phase 3 results for mosliciguat remain a pending catalyst.
Read from the article alone

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

biotech▲<1%
ROIV
clinical trials
drug approval
immunology
pharma
phase 3
pulmonary

Top 1 mover · tap to explore

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

What matters in this story

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

What matters in this story

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

How each ticker is affected

Track these names every morning.

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

What matters in this story

Next reads from the same story arc

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

What matters in this story

Next reads from the same story arc

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

How each ticker is affected

Track these names every morning.

Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2